Company Overview
| Stock Name | Republic HC |
|---|---|
| Stock Code | 08357 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家新加坡基本健康護理服務提供者,自2010年起以「Dr. Tan & Partners」名義經營全科醫療診治中心網絡,為常見病症提供治療方案,專營性健康及傳染病;2017年5月以「S Aesthetics」名義開展醫學美容診治中心業務,提供基本醫學美容服務。 |
| Listing Date | 2018-06-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港灣仔灣仔道165–171號樂基中心1402室 |
| Business Address (Hong Kong) | 香港皇后大道中99號中環中心57樓5705室 |
| Place of Incorporation | 開曼群島 |
| Listing Method | 發售以供認購 + 發售以供配售 |
| Listing Board | GEM |
| Website | republichealthcare.asia |
| Share Registrar | 宝德隆 |
| Registrar Contact | (852)2153 1688 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 0.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2018-06-01 to 2018-06-06 |
| Global Offering Shares | 130,000,000 shares |
| HK Public Offer Shares (Initial) | 13,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 117,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 520,000,000 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 78,000,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 90.6M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +10619% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 312,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約新加坡元2.0百萬元 |
| Period-End Cash Balance | 新加坡元1,993,771 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
RMB
Income Statement
| Item | 2016 | 2017 |
|---|---|---|
| Revenue | 7,127,991 | 9,956,894 |
| Other income and gains, net | 125,355 | 101,927 |
| Profit before tax | 2,272,808 | 2,048,001 |
| Income tax expense | -297,442 | -40,500 |
| Profit for the year | 1,975,366 | 2,007,501 |
| Profit attributable to owners | 1,975,366 | 2,007,501 |
Balance Sheet
| Item | 2016 | 2017 |
|---|---|---|
| Cash and cash equivalents | 2,064,243 | 1,993,771 |
| Trade and bills receivables | 15,392 | 78,038 |
| Inventories | 577,485 | 400,448 |
| Total current assets | 2,802,549 | 2,999,597 |
| Total assets | 3,265,753 | 3,826,300 |
| Total current liabilities | 1,351,704 | 2,123,246 |
| Total liabilities | 1,381,847 | 2,127,889 |
| Total equity | 1,883,906 | 1,698,411 |
| Equity attributable to owners | 1,883,906 | 1,698,411 |
Cash Flow Statement
| Item | 2016 | 2017 |
|---|---|---|
| Net cash from operating activities | 1,900,968 | 2,955,835 |
| Net cash from investing activities | -349,814 | -576,902 |
| Net cash from financing activities | -574,568 | -2,449,405 |
| Net increase in cash | 976,586 | -70,472 |
| Depreciation of PP&E | 144,220 | 263,611 |
| Purchase of PP&E | -352,219 | -576,902 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 0.79 |
|---|---|
| First Day Open | HK$ 0.65 |
| First Day Change | 31.67% |
| First Day Volume | 193155000.0 |
| First Day Turnover | 146948000.0 |
| Use of Proceeds | 1、約2.6百萬新加坡元或所得款項凈額約28.5%將用于策略性地拓展及鞏固DTAP診治中心的網絡;
2、約1.4百萬新加坡元或所得款項凈額約15.7%將用于增設新SA診治中心;
3、約4.3百萬新加坡元或所得款項凈額約46.9%用于持續吸納及挽留醫生和員工人才;
4、約0.6百萬新加坡元或所得款項凈額約6.4%將用于提升及改善信息科技基礎設施與系統;
5、約0.1百萬新加坡元或所得款項凈額約1.1%將用作設立中央藥庫;
6、約0.1百萬新加坡元或所得款項凈額約1.4%將用作一般營運資金。 |
Underwriting Syndicate
Sole Sponsor (1)
Titan Financial Services Limited CE BFR957
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陳致暹 | — |
| Company Secretary | 郭兆文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 英屬處女群島公司2號持股390,000,000股(75%);陳醫生透過該公司持有390,000,000股(75%)權益 |
|---|




